Group 1 - The core viewpoint of the article highlights that SINO PHARMACEUTICAL (02591) experienced a significant decline of over 13% after a two-week cumulative increase of 50% in its stock price [1] - As of the report, the stock price dropped by 13.64%, trading at 38 HKD with a transaction volume of 30.31 million HKD [1] - The Shanghai and Shenzhen Stock Exchanges announced that SINO PHARMACEUTICAL will be included in the Hong Kong Stock Connect effective from December 8, 2025, due to adjustments in the Hang Seng Composite MidCap Index [1] Group 2 - SINO PHARMACEUTICAL's self-developed long-acting GLP-1 receptor agonist, Ispaglutide α (Yinuo Qing®), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented alongside the new list on January 1, 2026 [1]

每经AI快讯，银诺医药-B(02591.HK)回吐逾13%，此前两周股价累计涨幅达50%。截至发稿，跌 13.64%，报38港元，成交额3031.07万港元。 （文章来源：每日经济新闻） ...

银诺医药-B(02591)回吐逾13%，此前两周股价累计涨幅达50%。截至发稿，跌13.64%，报38港元，成交 额3031.07万港元。 消息面上，上交所、深交所发布公告称，因恒生综合中型股指数实施成份股调整，根据有关规定，港股 通标的名单发生调整，将银诺医药调入港股通，自2025年12月8日起生效。此外，银诺医药宣布，公司 自主研发的超长效GLP-1受体激动剂依苏帕格鲁肽α（怡诺轻 ）正式纳入2025年国家医保药品目录，将 自2026年1月1日起与新版目录同步实施。 ...

Core Viewpoint - Silver诺医药-B (02591) experienced a decline of over 13% after a significant increase of 50% in the previous two weeks [1] Group 1: Stock Performance - As of the report, the stock price dropped by 13.64%, trading at 38 HKD with a transaction volume of 30.31 million HKD [1] Group 2: Regulatory Changes - The Shanghai and Shenzhen Stock Exchanges announced adjustments to the Hang Seng Composite MidCap Index, resulting in Silver诺医药 being included in the Hong Kong Stock Connect list, effective from December 8, 2025 [1] Group 3: Product Development - Silver诺医药's self-developed long-acting GLP-1 receptor agonist, Eysuparaglutide α (怡诺轻®), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented alongside the new list starting January 1, 2026 [1]

Core Points - The Shenzhen Stock Exchange announced on December 8 that due to the adjustment of the Hang Seng Composite Midcap Index, the list of eligible securities for the Hong Kong Stock Connect will be updated, effective from December 8, 2025 [1] Group 1: Company Adjustments - Four companies have been added to the Hong Kong Stock Connect: FWD Group (01828), Aux Group (02580), Sinopharm Group (02591), and Chery Automobile (09973) [1][3] - The adjustment reflects the ongoing changes in the market and the inclusion of mid-cap stocks in the investment framework [1]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Viewpoint - The company, Silver诺医药-B (02591), has successfully included its core product, Isuparaglutide α, in the latest version of China's National Medical Insurance Drug List (2025 edition) for the treatment of Type 2 Diabetes (T2D) [1] Group 1 - The inclusion of Isuparaglutide α in the National Medical Insurance Drug List is a significant milestone for the company [1] - The updated National Medical Insurance Drug List will officially take effect on January 1, 2026 [1]

Core Viewpoint - The announcement highlights that the core product, Isuparaglutide α, has been successfully included in the latest version of China's National Medical Insurance Drug List (2025 edition), effective from January 1, 2026, for the treatment of Type 2 Diabetes (T2D) [1][2]. Group 1: Product Details - Isuparaglutide α is the first domestically developed long-acting GLP-1 receptor agonist in China, approved for monotherapy and in combination with metformin for T2D treatment [1]. - Clinical studies have demonstrated that Isuparaglutide α has a rapid onset, strong and lasting efficacy, a long half-life, and good safety profile [1]. Group 2: Clinical Trial Results - In a Phase III clinical trial, T2D patients receiving Isuparaglutide α monotherapy (3.0 mg) showed a reduction in HbA1c levels by 1.1% after 4 weeks of treatment [1]. - In another randomized, double-blind, placebo-controlled Phase III trial, Isuparaglutide α at doses of 1.0 mg and 3.0 mg resulted in significant reductions in HbA1c levels of 1.7% and 2.2% respectively at week 24, demonstrating both statistical and clinical significance [1]. Group 3: Pharmacokinetics and Safety - Isuparaglutide α has an average half-life of 204 hours, allowing for low dosing frequency in long-term disease management [2]. - The safety profile of Isuparaglutide α is favorable, with no observed cases of drug-related grade 2 or higher hypoglycemia in clinical trials [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 本公告乃由廣州銀諾醫藥集團股份有限公司（「本公司」）作出，以向本公司股東 （「股東」）及有意投資者告知有關本公司近期的業務發展。 自願性公告 本公司核心產品納入《國家醫保藥品目錄》 － 依蘇帕格魯肽α安全性良好。在依蘇帕格魯肽α的臨床試驗中，均未觀察到藥 物相關2級或以上低血糖症案例。 有關本集團核心產品（即依蘇帕格魯肽α）的進一步詳情，請參閱本公司日期為 2025年8月7日的招股章程。 承董事會命 廣州銀諾醫藥集團股份有限公司 董事長 WANG QINGHUA博士 中華人民共和國，上海，2025年12月7日 董事會欣然宣佈，本集團核心產品（即依蘇帕格魯肽α）已成功納入中國最新版 《國家醫保藥品目錄》（2025年版） ...

Core Viewpoint - Silver诺医药-B (02591) has seen its stock price increase by over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The transaction volume reached 764.33 million HKD [1] Group 2: Market Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index as part of the quarterly review results [1] - The change will take effect on December 8, 2025 [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease [1] - All drugs are self-developed and possess global intellectual property rights, with a comprehensive global research and market layout [1]